Completed PHASE3 INTERVENTIONAL 2-arm NCT05156541

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (ING-HPV-1)

Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III)

Sponsor: SPP Pharmaclon Ltd.

Conditions Anogenital Warts Human Papillomavirus Infection

Interventions Interferon gamma human recombinant (IFN-G)

Updated 4 times since 2022 Last updated: Nov 30, 2021 Started: May 18, 2009 Primary completion: Jun 30, 2010 Completion: Jul 15, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anogenital Warts and Human Papillomavirus Infection and is currently completed. SPP Pharmaclon Ltd. leads this study, which shows 4 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2022 — Jul 2024 [monthly]

Completed PHASE3

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SPP Pharmaclon Ltd.

Data source: SPP Pharmaclon Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia